Envestnet Asset Management Inc. increased its stake in shares of Cambrex Co. (NYSE:CBM) by 5.2% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 38,393 shares of the biotechnology company’s stock after purchasing an additional 1,894 shares during the period. Envestnet Asset Management Inc.’s holdings in Cambrex were worth $1,797,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of CBM. Marshall Wace LLP purchased a new stake in Cambrex during the 1st quarter worth about $30,000. Hilton Capital Management LLC purchased a new stake in Cambrex during the 1st quarter worth about $94,000. Palouse Capital Management Inc. purchased a new stake in Cambrex during the 1st quarter worth about $242,000. Millennium Management LLC lifted its holdings in Cambrex by 102.2% during the 4th quarter. Millennium Management LLC now owns 7,164 shares of the biotechnology company’s stock worth $271,000 after purchasing an additional 3,621 shares in the last quarter. Finally, BNP Paribas Arbitrage SA lifted its holdings in Cambrex by 322.8% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,750 shares of the biotechnology company’s stock worth $301,000 after purchasing an additional 5,917 shares in the last quarter.
Several research firms have weighed in on CBM. Zacks Investment Research cut Cambrex from a “buy” rating to a “hold” rating in a report on Wednesday, July 24th. Craig Hallum cut Cambrex from a “buy” rating to a “hold” rating and set a $60.00 price target on the stock. in a report on Monday, August 12th. ValuEngine raised Cambrex from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 8th. William Blair cut Cambrex from an “outperform” rating to a “market perform” rating and set a $60.00 price target on the stock. in a report on Wednesday, August 7th. Finally, First Analysis cut Cambrex from a “strong-buy” rating to an “outperform” rating and raised their price target for the company from $45.00 to $55.00 in a report on Tuesday, May 7th. Five equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. Cambrex currently has a consensus rating of “Hold” and a consensus target price of $52.00.NYSE:CBM opened at $59.93 on Tuesday. The business’s 50-day moving average price is $52.40 and its two-hundred day moving average price is $44.25. Cambrex Co. has a twelve month low of $33.80 and a twelve month high of $69.43. The stock has a market cap of $2.02 billion, a P/E ratio of 25.50, a PEG ratio of 4.68 and a beta of 2.23. The company has a quick ratio of 1.77, a current ratio of 2.44 and a debt-to-equity ratio of 0.78.
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.
Featured Story: Do stock splits help investors?
Want to see what other hedge funds are holding CBM?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cambrex and related companies with MarketBeat.com’s FREE daily email newsletter.